An individual who meets any of the following criteria will be excluded from participation in this study: 1. Stage 4 severe chronic kidney disease or requiring dialysis (eGFR < 30) 2. Pregnant or breastfeeding. 3. Anticipated transfer to another facility that is not a study site within 72 hours. 4. Participants with known haematological diseases (G6PD deficiency) 5. Participants with chronic liver and kidney disease and reaching end-stage. 6. Participants with arrhythmia and chronic heart disease. 7. Participants known to have or hearing loss. 8. Participants known to have a mental disability. 9. Skin disorders (including rash, dermatitis, psoriasis). 10. Allergy to Ivermectin or its analogues. 11. Participants known to have filaria.

An individual who meets any of the following criteria will be excluded from participation in this study: 1. Stage 4 severe chronic kidney disease or requiring dialysis (eGFR < 30) 2. Pregnant or breastfeeding. 3. Anticipated transfer to another facility that is not a study site within 72 hours. 4. Participants with known haematological diseases (G6PD deficiency) 5. Participants with chronic liver and kidney disease and reaching end-stage. 6. Participants with arrhythmia and chronic heart disease. 7. Participants known to have or hearing loss. 8. Participants known to have a mental disability. 9. Skin disorders (including rash, dermatitis, psoriasis). 10. Allergy to Ivermectin or its analogues. 11. Participants known to have filaria.